NYSE:MYOV Myovant Sciences (MYOV) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free MYOV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$26.98▼$27.0050-Day Range$26.88▼$26.9952-Week Range$7.67▼$27.06Volume2.26 million shsAverage Volume1.17 million shsMarket Capitalization$2.62 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Myovant Sciences alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About Myovant Sciences Stock (NYSE:MYOV)Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.Read More Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. MYOV Stock News HeadlinesApril 18, 2024 | uk.finance.yahoo.comWorld Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline DrugsJanuary 15, 2024 | forbes.com2024 Could Be Women’s Health’s Long-Awaited, Much-Needed Standout YearApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. January 11, 2024 | finance.yahoo.comGlobal $67B+ Women's Health Market Landscape 2024-2030: Analysis by Age, Application and RegionJanuary 3, 2024 | finance.yahoo.comReAlta Life Sciences Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology ExecutivesDecember 28, 2023 | dailymail.co.ukVivek Ramaswamy wins legal battle over bid to force him to give evidence in multi-million dollar court case after GOP long-shot candidate claimed he was too busy campaigning to ...December 8, 2023 | finance.yahoo.comMetastatic Castration-Sensitive Prostate Cancer Market to Skyrocket at Astounding 22% CAGR During the Study Period (2019-2032), assesses DelveInsightNovember 21, 2023 | markets.businessinsider.comNCCN Announces Funding for Advanced Prostate Cancer Research ProjectsApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. October 22, 2023 | barrons.comMyovant Sciences, Ltd. (MYOV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsSeptember 26, 2023 | benzinga.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOVSeptember 12, 2023 | marketwatch.com4D Molecular Therapeutics Appoints Uneek Mehra Finance & Business ChiefAugust 29, 2023 | msn.comVivek Ramaswamy claims he is too busy campaigning to give evidenceAugust 29, 2023 | msn.com2024 Presidential candidate Vivek Ramaswamy trying to duck legal battle over his biotech empireAugust 28, 2023 | msn.comEXCLUSIVE: Vivek Ramaswamy claims he is too busy campaigning for President to give evidence in multi-million dollar court caseAugust 28, 2023 | msn.comVivek Ramaswamy cites campaign to duck deposition in buyout suitAugust 24, 2023 | msn.comBill Ackman Tells Vivek Ramaswamy How To Run For PresidentAugust 24, 2023 | finance.yahoo.comUterine Fibroids Treatment Global Market Report 2023August 21, 2023 | benzinga.comPresidential Hopeful Ramaswamy Predicts US Recession In 2024July 4, 2023 | uk.finance.yahoo.comHormone Therapy Global Market Report 2023June 26, 2023 | finance.yahoo.comHealth in Her HUE to Host Discussion Around Fibroids Awareness and Launch the Fibroids-focused Care Squad Program during Fibroid Awareness MonthJune 22, 2023 | benzinga.comAntibacterial Drugs Market to Reach US$ 62 Billion by 2031 | Fact.MR ReportMay 18, 2023 | finance.yahoo.comWomen's Health Market to Reach $63.02 Billion by 2030: Grand View Research, Inc.May 17, 2023 | finance.yahoo.comMyovant Sciences and Evidation Announce Survey Results of Unseen Burdens at Work and School of Individuals with Endometriosis and/or Uterine FibroidsMay 16, 2023 | marketwatch.comEndometriosis Treatment Drugs Market Top Competitors and Prediction Till 2030May 10, 2023 | marketwatch.comMetastatic Prostate Cancer Treatment Market Size: Growth Dynamics from 2023 to 2031May 8, 2023 | marketwatch.comMenstrual Cramps Treatment Market worth growing 4.0% at a CAGR by 2027See More Headlines Receive MYOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myovant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/26/2021Today4/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:MYOV Previous SymbolNASDAQ:MYOV CUSIPN/A CIK1679082 Webwww.myovant.com Phone442074003351FaxN/AEmployees407Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,980,000.00 Net Margins-48.47% Pretax Margin-42.81% Return on EquityN/A Return on Assets-39.36% Debt Debt-to-Equity RatioN/A Current Ratio1.57 Quick Ratio1.45 Sales & Book Value Annual Sales$230.97 million Price / Sales11.36 Cash FlowN/A Price / Cash FlowN/A Book Value($5.04) per share Price / Book-5.35Miscellaneous Outstanding Shares97,240,000Free Float95,388,000Market Cap$2.62 billion OptionableNot Optionable Beta2.17 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDavid C. MarekChief Executive Officer & DirectorJeffrey D. NornholdSenior VP-Pharmaceutical Operations & DevelopmentUneek MehraChief Financial & Business OfficerJuan Camilo Arjona FerreiraChief Medical OfficerMatthew LangSecretary, Chief Administrative & Legal OfficerKey CompetitorsSummit TherapeuticsNASDAQ:SMMTJanux TherapeuticsNASDAQ:JANXIndiviorNASDAQ:INDVEvotecNASDAQ:EVOMorphoSysNASDAQ:MORView All Competitors MYOV Stock Analysis - Frequently Asked Questions How were Myovant Sciences' earnings last quarter? Myovant Sciences Ltd. (NYSE:MYOV) released its earnings results on Tuesday, October, 26th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.11. The company had revenue of $77.90 million for the quarter, compared to analysts' expectations of $72.67 million. During the same quarter last year, the firm posted ($0.75) earnings per share. What other stocks do shareholders of Myovant Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myovant Sciences investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Coty (COTY), Gilead Sciences (GILD), Micron Technology (MU), VBI Vaccines (VBIV), NVIDIA (NVDA) and Carnival Co. & (CCL). When did Myovant Sciences IPO? Myovant Sciences (MYOV) raised $176 million in an IPO on Thursday, October 27th 2016. The company issued 13,000,000 shares at $12.00-$15.00 per share. Citigroup, Cowen and Company, Evercore ISI and Barclays acted as the underwriters for the IPO and JMP Securities and Baird were co-managers. This page (NYSE:MYOV) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressThe only accurate crypto trading system I know …Weiss RatingsBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myovant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
